The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Preprints

A preprint whose numbers changed substantially at publication — what changed since

BA
b.aaltoTL2 Moderator25 Jul 2025#1

On the subject in the title: A preprint whose numbers changed substantially at publication — what changed since Working notes rather than a conclusion.

Session topic: STEP 2 (Lancet, 2021). Please read it before posting; the discussion is much better when everyone has.

The question I would like us to start with is what the trial set out to estimate, rather than what it found. Once that is on the table we can talk about whether the design could have answered it, and only then about the numbers.

Specific things I would like covered: the population and how far it generalises, how discontinuation was handled, whether the comparator was a fair one, and what the absolute rather than relative effect looks like.

I will summarise at the end and the summary will feed the relevant digest page.

9 likes 12mo
RV
r.vukovicTL2 Moderator23 Aug 2025#2

Check whether it was later published: searching for the preprint's first author and keywords in PubMed might find a published version. The published version is the stronger citation if it exists.

14 likes 11mo
KO
k.otieno_statsTL3Statistician13 Sep 2025 · edited#3

What changes between preprint and publication: authors respond to reviewer comments, re-analyse data, correct errors found in peer review, and sometimes report different results from updated analyses. The published version is not the same as the preprint.

28 likes 10mo
ES
e.steinerTL2 Moderator1 Oct 2025#4
b.aalto, post #1: On the subject in the title: A preprint whose numbers changed substantially at publication — what changed since Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is much better when everyone has. The question I would like us to start with is what the trial set… Go to post

On post #3 — agreed on the reasoning, with one qualification.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

0 likes in reply to #1 10mo
SS
system_suitabilityTL3Analytical chemist18 Oct 2025#5

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

2 likes 9mo
NI
n.ibarraTL2 Moderator3 Nov 2025#6

Server repositories: medRxiv for medicine, bioRxiv for biology. Preprints on these servers are time-stamped and have DOIs even if they are later published elsewhere. Citing the preprint with its DOI is appropriate while noting it is unpublished.

9 likes 9mo
PI
p.iyer_pharmdTL3Pharmacist19 Nov 2025#7

post #6 is right about the mechanism and I think understates the practical bit.

Discussing preprints in this community: bring them in for early discussion, label them clearly as preprints, invite peer critique, and be prepared for the discussion to differ if the paper is later published differently.

20 likes 8mo
ZO
z.okonkwoTL2 Moderator4 Dec 2025#8
k.otieno_stats, post #3: What changes between preprint and publication: authors respond to reviewer comments, re-analyse data, correct errors found in peer review, and sometimes report different results from updated analyses. The published version is not the same as the preprint. Go to post

Worth separating two things that post #4 runs together.

Unrefereed work is not worthless. A great deal of it survives review substantially unchanged. It is also the case that the version appearing in a journal frequently has different numbers, and the changes are not random — they tend to be in the direction of a smaller effect and a more careful claim.

0 likes in reply to #3 8mo

Suggested topics

TopicParticipantsRepliesViewsActivity
Preprint servers and what screening they do — the long version
On the subject in the title: Preprint servers and what screening they do — the long version Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
APNEYASSRM+7 11 26k 4mo
Tracking a preprint to publication: a worked example
Tracking a preprint to publication: a worked example Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 1 ( N Engl J Med , 2021). Please read it before…
VBUCRSDTSB+133 147 15k 7mo
[2026 update] Conference abstracts as evidence: the weakest common citation
Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-4 ( JAMA , 2024) and finding…
JVVNJB 2 48k 7mo
Citing a preprint in a maintained document: our rule and its reasoning
On the subject in the title: Citing a preprint in a maintained document: our rule and its reasoning Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a…
OVSLTN 2 467 4mo
Why a preprint's supplementary material is often the best part
Why a preprint's supplementary material is often the best part I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…
SCTWJSMSH+38 42 863 22mo

Related topics — sharing the tags risk of bias, effect size, needs a source

TopicParticipantsRepliesViewsActivity
What the published dose-response for semaglutide actually looks like above 2.4 mg
What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…
FEFTRW 2 10k 3mo
Cagrilintide's dosing interval and the pharmacokinetics behind it
Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SELECT ( N Engl J Med ,…
BLCMABPRM+98 105 24k 10mo
Publication patterns in the BPC-157 literature, examined
Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of…
MMMHEIDVBO+40 45 3.4k 21h
Criticising the method without criticising the authors — one year on
On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…
KOSKJNAKSC+16 20 61k 11mo
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence
Posting this under the heading it deserves: Tesamorelin has an approved indication — what that changes about the evidence Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with…
RLHFTDIBBW+63 68 18k 14mo